. Author manuscript; available in PMC: 2018 Apr 9.

Published in final edited form as: J Urol. 2009 Dec;182(6):2653–2658. doi: 10.1016/j.juro.2009.08.056

Table 4.

Comparison of PCPT risks to actual risks in subgroups of the EDRN cohort

	No.	Prostate Ca (%)	Av PCPT Risk (%)	AUC (95% CI)
All	645	43.4	45.1	0.691 (0.650–0.732)
PSA 4 ng/ml or less	224	28.1	33.6	0.638 (0.558–0.718)
PSA greater than 4 ng/ml	421	51.5	51.1	0.656 (0.604–0.708)
Normal DRE	510	39.8	41.8	0.622 (0.573–0.672)
Abnormal DRE	135	57.0	57.4	0.839 (0.771–0.908)
White	559	44.0	45.1	0.694 (0.650–0.737)
African-American	47	51.1	45.4	0.697 (0.541–0.852)
Age 65 yrs or older	234	51.3	49.9	0.649 (0.579–0.720)
Age younger than 65 yrs	411	38.9	42.3	0.705 (0.654–0.755)
Family history	162	50.0	46.8	0.650 (0.566–0.734)
No family history	483	41.2	44.5	0.699 (0.651–0.746)